Meeting
2017 ASCO Annual Meeting
Patterns of use of CNS prophylaxis in DLBCL in a large health system.
Authors
Michael A. Thompson
Aurora Advanced Healthcare, Milwaukee, WI
Michael A. Thompson , Sol Atienza Yoder , Lisa Ann Robinson , Renee Aranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7562)
DOI
10.1200/JCO.2017.35.15_suppl.7562
Abstract #
7562
Poster Bd #
324
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Quality Care Symposium
Can high-dose methotrexate be safely administered to outpatients?
First Author: Briana Genge
Poster
2021 ASCO Annual Meeting
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.
First Author: Catherine Thieblemont
Poster
2022 ASCO Annual Meeting
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
First Author: Umberto Vitolo
Poster
2022 ASCO Annual Meeting
Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial.
First Author: Franck Morschhauser